Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) insider Mark Hopman sold 775 shares of the firm’s stock in a transaction on Monday, November 16th. The shares were sold at an average price of $16.22, for a total value of $12,570.50. Following the completion of the sale, the insider owned 54,143 shares of the company’s stock, valued at approximately $878,199.46. This trade represents a 1.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Mark Hopman also recently made the following trade(s):
- On Monday, October 26th, Mark Hopman sold 821 shares of Beta Bionics stock. The shares were sold at an average price of $20.00, for a total value of $16,420.00.
- On Wednesday, October 14th, Mark Hopman sold 775 shares of Beta Bionics stock. The stock was sold at an average price of $17.35, for a total transaction of $13,446.25.
- On Thursday, October 1st, Mark Hopman sold 370 shares of Beta Bionics stock. The shares were sold at an average price of $18.96, for a total transaction of $7,015.20.
- On Wednesday, September 16th, Mark Hopman sold 30,779 shares of Beta Bionics stock. The shares were sold at an average price of $20.13, for a total transaction of $619,581.27.
- On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The stock was sold at an average price of $18.46, for a total transaction of $680,620.20.
- On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total transaction of $101,798.97.
Beta Bionics Trading Down 2.6%
Shares of Beta Bionics stock traded down $0.39 during midday trading on Wednesday, reaching $14.33. The company had a trading volume of 1,376,418 shares, compared to its average volume of 1,176,370. The company has a market capitalization of $779.12 million, a price-to-earnings ratio of -7.79 and a beta of 3.44. Beta Bionics, Inc. has a 1-year low of $8.80 and a 1-year high of $32.71. The stock has a fifty day simple moving average of $18.29 and a 200 day simple moving average of $14.86.
Beta Bionics (NASDAQ:BBNX – Get Free Report) last announced its quarterly earnings data on Tuesday, October 27th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.01. Beta Bionics had a negative return on equity of 27.33% and a negative net margin of 65.31%. The firm had revenue of $35.51 million during the quarter. Sell-side analysts expect that Beta Bionics, Inc. will post -2.04 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Beta Bionics during the second quarter worth about $52,340,000. Eversept Partners LP lifted its stake in Beta Bionics by 108.6% in the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after acquiring an additional 736,576 shares in the last quarter. Bank of America Corp DE acquired a new position in Beta Bionics during the 2nd quarter worth approximately $8,566,000. Perceptive Advisors LLC grew its stake in shares of Beta Bionics by 39.8% during the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after acquiring an additional 240,000 shares in the last quarter. Finally, Bruce & Co. Inc. bought a new position in shares of Beta Bionics during the 1st quarter worth approximately $5,518,000.
Analyst Ratings Changes
A number of brokerages have issued reports on BBNX. Wells Fargo & Company started coverage on Beta Bionics in a report on Wednesday, September 23rd. They set an “overweight” rating and a $28.00 target price on the stock. Piper Sandler reissued an “overweight” rating and set a $24.00 price objective (up from $20.00) on shares of Beta Bionics in a research note on Wednesday, October 28th. Jefferies Financial Group started coverage on shares of Beta Bionics in a report on Monday, October 12th. They set a “buy” rating and a $30.00 price objective for the company. Truist Financial boosted their target price on Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, September 24th. Finally, William Blair assumed coverage on Beta Bionics in a research report on Friday, August 21st. They issued a “market perform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.69.
Read Our Latest Stock Report on BBNX
About Beta Bionics
Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user’s body weight and adjusts insulin delivery based on glucose readings.
Recommended Stories
- Five stocks we like better than Beta Bionics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
